Study sponsor Cell Therapeutics announced that Pixantrone achieved the primary efficacy endpoint, and in April 2009 began a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for Pixantrone to treat relapsed or refractory aggressive NHL.
Pixantrone achieved the primary efficacy endpoint. This was what Study sponsor Cell Therapeutics announced. Pixantrone in April 2009 began a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for Pixantrone. This was to treat relapsed or refractory aggressive NHL. This was what Study sponsor Cell Therapeutics announced.